Senseonics Revenue Surges 140% as New Pump Integration Nears Launch

Key Points

• Revenue rose 140% to $19.6 million, and Senseonics raised its 2026 revenue guidance to $68 million–$70 million for the third consecutive quarter. Quarterly gross margin was 62%, and the company ended with about $127 million in cash and restricted cash.
• Senseonics expects to launch its Eversense integration with Beta Bionics’ insulin pump in about a week, following its partnership with Sequel Med Tech. Real-world glucose time in range was about 76% for patients using Eversense with the Sequel pump, versus 66% for Eversense users overall.
• The company is developing Freedom, a fully implanted yearlong sensor, and plans to submit data for an investigational device exemption in the first half of 2027; a potential launch is targeted for mid-2028, subject to regulatory approval. Senseonics is targeting EBITDA breakeven in 2028.

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS reported quarterly revenue of $19.6 million, up 140% from a year earlier, as the continuous glucose monitoring company expands access to its implantable Eversense sensor and prepares for a new insulin pump integration.

President and CEO Tim Goodnow told the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum that Senseonics raised its full-year revenue guidance to $68 million to $70 million and its gross margin outlook to at least 60%. It was the third consecutive quarter in which the company increased its annual guidance, he said.

The company posted a 62% gross margin for the quarter and had approximately $127 million in cash and restricted cash. Goodnow said Senseonics also raised growth capital earlier in 2026.

Growth and pump partnerships

Senseonics’ Eversense sensor is inserted under the skin in a medical office and remains in place for a year. The current system also uses an external transmitter. Goodnow said the longer-lasting sensor offers an alternative to devices that require more frequent replacement, although patients must undergo an insertion procedure.

Approximately 90% of Eversense patients are switching from another continuous glucose monitor, with the remainder new to the technology, Goodnow said. He attributed the company’s near-doubling of revenue this year to new patient growth and said it was on track to approach similar growth in 2027.

Senseonics transitioned away from its partnership with Ascensia Diabetes Care at the start of 2026, and its current results reflect the standalone business, Goodnow said.

The CEO also highlighted the integration of Eversense with automated insulin delivery systems. Senseonics partnered with Sequel Med Tech on its twiist pump and expects to launch an integrated product with Beta Bionics in about a week, he said. Goodnow anticipates at least two additional pump partnerships by 2028, but declined to commit to an earlier date.

Goodnow said real-world data showed glucose time in range of about 66% for a population using Eversense, rising to 76% when paired with the Sequel pump. He attributed the result to the yearlong sensor and Sequel’s Loop algorithm.

Marketing and access

About 60% of new patients come through direct-to-consumer marketing, primarily online and through social media, while the remaining 40% come through health care professionals, Goodnow said. Roughly 85% of revenue comes from the United States and 15% from Europe, where the company operates in four markets.

To make insertions more accessible, Senseonics has built an Eon Care network of about 100 contracted nurses. Goodnow expects the network to grow to approximately 120 nurses over the next couple of months and eventually to hundreds as the company expands geographically.

Goodnow said the company has historically seen retention of about 75% from a patient’s first sensor to the second, approximately 85% from the second to the third, and more than 90% among patients on their third or subsequent sensors. Senseonics previously sold 90-day and 180-day versions before moving to the current 365-day product.

Fully implanted sensor in development

Senseonics is developing Freedom, a fully implanted sensor designed to operate for a year without a component on the skin. Goodnow said the company recently began its first human insertions and plans to use the resulting data to support an investigational device exemption submission in the first half of 2027.

He said the company anticipates a pivotal trial of roughly 100 patients and a potential market launch in mid-2028, subject to the regulatory process. Senseonics also is developing Gemini, an intermediate product with an internal battery that Goodnow said is more targeted toward people with type 2 diabetes.

Goodnow said Senseonics is targeting EBITDA breakeven in 2028, with profitability afterward. As Freedom is introduced and the company gains scale, he expects gross margin to reach 70%.

About Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS)

Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company's product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.